The Invalids have put substantial pressure on our stock
The Invalids have put substantial pressure on our stock since NP announced HIV as a Monotherapy and maybe even before; considering the dilution longs suffered while raising little money with previous leaders.
Their narrative was to pin point Nader as bad to sway votes for a new BOD. Our SP took a hit during the proxy battle while they were invalid all along.
The narrative stayed the same and one would think they were good reasons. However, I chose not to judge because I understand that current management has been trying to break themselves free from the invalids self-inflicting wounds laid upon us.
Leaving CROs and not putting all of our eggs in one CRO is a start of something awesome. Diversity and strategic partnerships.
One: SymBio has had over 55 FDA approvals, over 40 years of data management, over 200 clinical trials, has 1,200 clinical sites and worked with 85,000 patients.
Chris Recknor believes Long Haulers is attached to Epstein Barr virus, CVM, etc and many researchers have pointed out women suffer from LHs at a higher rate. With the data that CR has seen, it would make sense as to why this CRO is running LH.
They specialize in women health, are a world class organization and have offices in Europe as well.
CytoDyn released a PR basically stating that the FDA is allowing them to submit portions of the BLA in….regardless of what gaps to fill. A Rolling review, without the negative spin.
Voted FOR ALL, to give this company the chance to grow with Brazil, Philippines and all 60+ indications and CROs.
All these BTDs, with an effective and safety profile drug.
I’m also anticipating possible results on if the Monotherapy HIV clients taking our drug ever got Covid or Long Haulers or didn’t.
There’s so much more information we will get out of our CROs for more possible BTDs. I’m here for all of it.
22
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...
Continue Reading
A faceted dome in the Alabama woods is about as far from a cookie-cutter reroof as it gets. Ridgeline Roofing & Restoration’s 2026 Excellence Award from Brava Roof Tile matters because the job in Pell City demanded the sort of painstaking field execution that separates a capable contractor from a crew merely moving shingles fast. Geometry Is Where Easy Claims Go to Die...
Continue Reading
Infrastructure outfits rarely make much noise when they reshuffle leadership, but Halff’s Nov. 18 announcement deserves a closer look than the usual executive-title confetti. The employee-owned consulting firm has put Greg Carpenter in the chief people officer seat and named Leigh Hollis chief delivery officer. One role is aimed squarely at the human machinery; the...
Continue Reading
A cold snap is not a magic off switch for mosquitoes, ticks, or rodents, and that is the sober point behind the National Pest Management Association's fall and winter 2026 Public Health Pest Index. The group is flagging conditions, not predicting that every household in a named city will face an infestation or illness. Still, mild temperatures, rain, flooding, and plenty...
Continue Reading
Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...
Continue Reading
A pile of soon-to-expire FSA cash is a peculiar sales catalyst, but Polsen Health has found one. The Amsterdam-based preventative-health wearable company is partnering with Flex to let customers pay for every Polsen watch and strap using eligible HSA or FSA funds at checkout. No reimbursement chase, no claim forms, and buyers can split the cost with another card. For a...
Continue Reading
Azure’s next bottleneck may be the plumbing between chips, not the chips alone. Microsoft and Intel announced on Nov. 18, 2026, a long-term expansion of their already ancient partnership aimed at shaping select pieces of Azure infrastructure for cloud and AI demand. That sounds dry, because infrastructure announcements usually do. But this one deserves a closer look: it...
Continue Reading
Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...
Continue Reading
Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...
Continue Reading
Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...
Continue Reading
Top 5 Most Recently Viewed Articles
Symbotic Inc. Under Investigation for Securities Violations There has been a significant development for investors of Symbotic Inc. As concerns about the Company’s financial practices have arisen, the Schall Law Firm has initiated an investigation. This effort is aimed at ensuring shareholders are informed and protected amid allegations of misleading statements related...
Continue Reading
Turning Point Brands Gets a Positive Buy Rating Recently, Turning Point Brands (NYSE: TPB) earned a favorable Buy rating from Roth/MKM, along with a price target set at $50. This company is known for its wide range of consumer brands in the nicotine, tobacco, and cannabis markets, particularly recognized for its popular rolling papers and moist snuff products. Growth in...
Continue Reading
NeuroSense Therapeutics Achieves Commercial Manufacturing Scale-Up NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a pioneering biotechnology firm dedicated to developing innovative treatments for severe neurodegenerative diseases, has announced a major milestone in its commercial journey. The company has successfully scaled up its production of PrimeC, preparing for...
Continue Reading
Unveiling the Future of Peptide Stability with Azapeptide Synthesis In this informative webinar, participants will discover how strategies involving azapeptides can significantly enhance the stability of peptides and improve workflows related to synthesis. Attendees will delve into techniques for incorporating aza-amino acids within peptides that utilize traditional amino...
Continue Reading
Ascent Solar Technologies Hits 52-Week Low Ascent Solar Technologies, recognized for its cutting-edge thin-film photovoltaic modules, is currently going through a challenging period. The company's stock has reached a 52-week low of $2.32, reflecting an astonishing nearly 99.6% decline over the past year. This drastic drop underscores the significant hurdles the company...
Continue Reading